Oxford, UK – 25th May 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a workshop at this year’s European Society of Human Genetics (ESHG) conference in Amsterdam. The workshop, entitled “Adding value through analysis”, will take place on Saturday the 28th of May and will reveal details of OGT’s new comprehensive targeted sequencing service. Hosted between 11:45 and 13:15 in room E104-105 of the Congress Centre, the seminar will feature presentations from OGT team members including Chief Executive Officer Mike Evans, DPhil, Senior Computational Biologist Jolyon Holdstock, PhD and Head of Computational Biology Volker Brenner, PhD. Each talk will focus on key elements of the new service, culminating in an informal discussion over lunch provided by OGT.
The sheer volume of data generated by next generation sequencing can present a serious obstacle to researchers in terms of data management, storage and analysis. To address this challenge, OGT’s targeted sequencing service is designed to provide meaningful results rather than insurmountable data sets, achieved by utilising OGT’s internationally recognised probe design and data analysis expertise plus independently accredited quality control procedures. The sequencing options available combine seamlessly with other aspects of OGT’s Genefficiency™ genomic services offering to provide the most flexible and powerful solution available for driving your genomic research forward.
To register for the workshop please visit www.ogt.co.uk/go/register
To find out more about the full range of products and services offered by OGT, visit www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: email@example.com
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.